Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Back to Search
Print
Bookmark Trial

NCT00661661

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
National hospital Organization Nagoya Medical Center
Nagoya, Aichi, 460-0001, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects who have completed their participation in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Serious medical conditions that would make treatment with CP-690,550 potentially
unsafe

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Rheumatoid ArthritisStudy Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis NCT00141830
  1. Largo, Florida
  2. Palm Harbor, Florida
  3. Sarasota, Florida
  4. Boise, Idaho
  5. Kansas City, Kansas
  6. Frederick, Maryland
  7. Albuquerque, New Mexico
  8. Charlotte, North Carolina
  9. Duncansville, Pennsylvania
  10. Austin, Texas
  11. Dallas, Texas
  12. San Antonio, Texas
  13. Spokane, Washington
  14. La Crosse, Wisconsin
  15. Penticton, British Columbia
  16. Newmarket, Ontario
  17. Toronto, Ontario
  18. Montréal, Quebec
  19. Trois-Rivières, Quebec
  20. Saskatoon, Saskatchewan
  21. Quebec,
  22. Budapest,
  23. Békéscsaba,
  24. Veszprém,
  25. Brescia,
  26. Genova,
  27. Pavia,
  28. Roma,
  29. Siena,
  30. Jalisco, Guadalajara
  31. Delegacion Cuahutemoc,
  32. Andalucia,
  33. Castilla la Mancha,
  34. Comunidad Valenciana,
  35. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisStudy Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 NCT01059864
  1. Birmingham, Alabama
  2. Huntsville, Alabama
  3. Gilbert, Arizona
  4. Scottsdale, Arizona
  5. Upland, California
  6. Jacksonville, Florida
  7. Dayton, Ohio
  8. Mayfield Village, Ohio
  9. Greenville, South Carolina
  10. Allen, Texas
  11. Seoul,
  12. Seoul,
  13. Seoul,
  14. Seoul,
  15. Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisEffects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) NCT01164579
  1. Gilbert, Arizona
  2. Huntington Beach, California
  3. Upland, California
  4. Ormond Beach, Florida
  5. Pinellas Park, Florida
  6. St. Petersburg, Florida
  7. Oklahoma City, Oklahoma
  8. Allen, Texas
  9. Buenos Aires,
  10. Buenos Aires,
  11. Buenos Aires,
  12. Valdivia, Region XIV
  13. Osorno, X Region
  14. Split,
  15. Zagreb,
  16. Hostivice,
  17. Praha 11 - Chodov,
  18. Praha 1,
  19. Praha 1,
  20. Praha 2,
  21. Uherske Hradiste,
  22. Zlin,
  23. Zlin,
  24. Balatonfured,
  25. Budapest,
  26. Budapest,
  27. Debrecen,
  28. Gyor,
  29. Mexico, D. F.
  30. Mexico, D.f.
  31. Mexico, Distrito Federal
  32. Chapultepec,
  33. Chihuahua,
  34. Mexico D.F.,
  35. San Luis Potosi,
  36. Bialystok,
  37. Poznan,
  38. Torun,
  39. San Juan,
  40. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisThree Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks NCT00147498
  1. Upland, California
  2. Clearwater, Florida
  3. Miami, Florida
  4. New Port Richey, Florida
  5. Ocala, Florida
  6. Orlando, Florida
  7. Port Richey, Florida
  8. Tampa, Florida
  9. Dubuque, Iowa
  10. Dubuque, Iowa
  11. Concord, New Hampshire
  12. Plainview, New York
  13. Charlotte, North Carolina
  14. Hickory, North Carolina
  15. Hickory, North Carolina
  16. Dayton, Ohio
  17. Ducansville, Pennsylvania
  18. Johnstown, Pennsylvania
  19. Charleston, South Carolina
  20. Columbia, South Carolina
  21. Nashville, Tennessee
  22. Dallas, Texas
  23. Everett, Washington
  24. Tacoma, Washington
  25. Gent,
  26. Goiânia, GO
  27. Goiânia, GO
  28. Curitiba, PR
  29. São Paulo, SP
  30. São Paulo, SP
  31. Edmonton, Alberta
  32. Victoria, British Columbia
  33. Saint John's, Newfoundland and Labrador
  34. London, Ontario
  35. Toronto, Ontario
  36. Berlin,
  37. Dresden,
  38. Hamburg,
  39. Hildesheim,
  40. Leipzig,
  41. Muenchen,
  42. Neubrandenburg,
  43. Wiesbaden,
  44. Firenze,
  45. Genova,
  46. Pavia,
  47. México, D.f.
  48. Tlalpan Seccion 16, DF
  49. Guadalajara, Jalisco
  50. Aguascalientes,
  51. San Luis Potosí,
  52. Kosice,
  53. Piestany,
  54. Zilina,
  55. L´hospitalet de Llobregat, Barcelona
  56. Santiago de Compostela, La Coruña
  57. Barcelona,
  58. Guadalajara,
  59. Madrid,
  60. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Official Title  ICMJE A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis
Brief Summary The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this study after they have completed participation in another "qualifying" study of CP-690,550.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Rheumatoid Arthritis
Intervention  ICMJE Drug: CP-690,550
5 mg BID up to 10 mg BID until launch
Study Arms  ICMJE Experimental: CP-690,550
Intervention: Drug: CP-690,550
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 15, 2014)		487
Original Estimated Enrollment  ICMJE
 (submitted: April 15, 2008)		240
Actual Study Completion Date  ICMJE December 2013
Actual Primary Completion Date December 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects who have completed their participation in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Exclusion Criteria:

  • Serious medical conditions that would make treatment with CP-690,550 potentially unsafe
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00661661
Other Study ID Numbers  ICMJE A3921041
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP